key: cord-0865191-pcqq9vlu
authors: Sahilu, Tamiru; Sheleme, Tadesse; Melaku, Tsegaye
title: Severity and Mortality Associated with Steroid Use among Patients with COVID-19: A Systematic Review and Meta-Analysis
date: 2021-05-06
journal: Interdiscip Perspect Infect Dis
DOI: 10.1155/2021/6650469
sha: aec8382c09b6a72fc87ab7410e32eafca4a2c968
doc_id: 865191
cord_uid: pcqq9vlu

BACKGROUND: There are controversial suggestions about steroid use to treat patients infected with COVID-19. Conclusive evidence regarding the use of steroids to treat COVID-19 is still lacking. This meta-analysis aimed to determine the mortality and severity associated with corticosteroid therapy compared to noncorticosteroid treatment in patients with COVID-19. METHODS: The information was collected from electronic databases: PubMed, CINAHL, the Cochrane Library, clinicaltrials.gov, and Google scholar through January 30, 2021. Risk ratios (RRs) with 95% confidence intervals (CIs) were performed using random effect models. Endnote citation manager software version X9 for Windows was utilized to collect and organize search outcomes (into relevant and irrelevant studies) and to remove duplicate articles. RESULTS: Thirty-two studies were included in the meta-analysis, including 14,659 COVID-19 patients. No significant differences in mortality between the steroid and nonsteroid treatment groups (RR = 0.95; 95% CI: 0.80–1.13; p = 0.57). There was no significant reduction in mortality in critically ill COVID-19 patients treated with corticosteroid (RR = 0.89; 95% CI: 0.62–1.27; p = 0.52). Significant differences were observed in severe disease conditions between the steroid and nonsteroid treatment groups (RR = 1.10; 95% CI, 1.03–1.19, p = 0.007). CONCLUSION: There was no significant difference in all-cause mortality between the steroid and nonsteroid treatment users' of COVID-19 patients. There was no significant reduction of all-cause mortality in critically ill COVID-19 patients treated with corticosteroids.

Coronavirus disease-19 was first identified at the end of 2019 in Wuhan City, China. It rapidly spread in China and other countries throughout the world [1, 2] . In March 2020, the World Health Organization characterized the disease as pandemic [3] . As of May 21, 2020, more than five million confirmed cases have been documented and several death cases reported globally. It is affecting 213 countries and territories around the world and 2 international conveyances [4] . Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is identified as the cause of COVID-19 [5] .

Currently, there is no drug confirmed by clinical trial to prevent or treat COVID-19. However, more than 300 active clinical treatment trials are under investigation [6] . Drugs that are already marketed for other conditions are being off-label used. For example, antimalarial medications chloroquine and hydroxychloroquine are widely used to treat COVID-19 [7] . A multinational registry analysis debunked the benefit of hydroxychloroquine or chloroquine when used alone or with a macrolide. e finding of the study showed that each of these regimens was associated with decreased in-hospital survival and an increased frequency of ventricular arrhythmias when used for the treatment of COVID-19 [8] . Remdesivir is another drug being used as a promising option for treating COVID-19 based on laboratory experiments [9] .

Corticosteroids were widely used to treat severe acute respiratory syndrome coronavirus-1(SARS-CoV-1) and Middle East respiratory syndrome coronavirus (MERS) during their outbreaks and are being used in patients with COVID-2019 [10] . Up to 70% of critically ill patients are receiving systemic corticosteroids. It is identified that patients treated with a corticosteroid had more clinical symptoms, a higher inflammation index, and more abnormalities on chest computed tomography [11] . A study showed that the use of high-dose corticosteroids increases the risk of death in patients with severe COVID-19 [12] , indicating several controversial issues about the use of the steroid to treat patients infected with COVID-19. It is suggested that available evidence does not endorse the use of a steroid for COVID-19 patients, which may cause several side effects [13] . However, it is believed that short-term glucocorticoid therapy with small-or medium-dose could be beneficial for patients with severe conditions [14] . According to the World Health Organization (WHO) guidelines recommendation, glucocorticoids should only be used under clinical trial conditions [15] . Conclusive evidence regarding the use of the steroid to treat COVID-19 is still lacking. erefore, this study aims to summarize the current evidence of the severity and mortality associated with steroid therapy for patients with COVID-19 which will support us in making the best decision in the management of the COVID-19.

Analyses were performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [16] . is study was registered in PROSPERO with registration number CRD42020185773.

e information was collected from electronic databases: PubMed, CINAHL, the Cochrane Library, clinicaltrial.gov, and Google scholar. ere was no limitation applied to the language. e reference list of all identified articles was searched for additional studies. en, an extensive list of search terms was prepared by the analysis of title, abstract, and keywords of retrieved articles. A fullscale search of databases in PubMed, CINAHL, the Cochrane Central Register of Controlled Trials, clinicaltrial. gov, and Google scholar from inception to January 30, 2021, was performed. No language restriction was imposed during the identification of studies. Flow diagram was used to summarize the number of studies identified, screened, excluded, and finally included in the study. 

Two reviewers independently carried out a literature search and examined relevant studies and sequentially screened their titles and abstracts for eligibility. e full texts of potentially eligible studies were retrieved. Disagreements were solved in a discussion. A screening guide was used to ensure that all review authors reliably apply the selection criteria.

Criteria. Randomized controlled trials (RCTs), observational studies, prospective and retrospective comparative cohort studies, and case-control studies were eligible for the review. e review considered all articles comparing corticosteroid with noncorticosteroid treatment for patients with the diagnosis of COVID-19. Nonhuman studies and studies that did not report mortality and severity data were excluded from the review. e outcome considered was mortality, death within the hospital (all-cause mortality) of COVID 19 patients. e other outcome studied was the number of severe cases in the two groups (corticosteroid versus noncorticosteroid treatment groups).

were assessed by two independent reviewers for methodological validity before inclusion in the review. Observational studies were assessed using Newcastle-Ottawa Scale (NOS), which consists of three domains: (1) subject selection, (2) comparability of the study groups, and (3) assessment of outcome(s). A score of 0-9 was allocated to each study. A standardized Cochrane risk of bias tool was used for the randomized controlled trial (RCT). Any disagreements that arise between the reviewers were resolved through discussion.

2.6. Data Extraction. Two reviewers independently extracted data from the studies using a predesigned format prepared. Data that were extracted include first author, a region of study, included population, study design, sample size, comparator group, patient status, age, gender, interventions, mortality, and severity. Severe cases were characterized as patients admitted to ICU or on invasive mechanical ventilation.

To perform a meta-analysis, Review Manager 5.4 (Copenhagen: e Cochrane Collaboration, 2014) was used. e outcome variables were calculated using the Mantel Haenszel formula. Risk ratios (RRs) were reported with 95% confidence intervals (CIs) for the variables. e p value was two-tailed, and the statistical significance was set at ≤0.05. Heterogeneity was assessed with the Q-statistic test and the I 2 test. e I 2 statistic measured the percentage of total variation across the studies due to clinical or methodological heterogeneity instead of chance. e significant Q statistics (p < 0.05) indicated heterogeneity across the studies; thus, a random effect model was utilized. Substantial heterogeneity was represented by I 2 for >50%.

e search returned a total of 1419 (PubMed: 85, Google Scholar: 1290, clinicaltrials.gov: 24, Cochrane Library: 1, and other sources: 19) citations, of which 40 were duplicates. According to the exclusion criteria, 1292 citations were excluded after the title and abstract screening. Figure 1 shows the study selection processes.

e present metaanalysis included 28 observational studies [12, and 4 RCTs [44] [45] [46] [47] . ese studies included 14,659 patients with the diagnosis of COVID-19 who received corticosteroids (5,830 patients) or noncorticosteroids (8,829 patients). Tables 1 and 2 list the characteristics of the included studies. All eligible studies were published in 2020/21. Individual assessment of the risk of bias was presented in Table 3 . In the 26 included studies [17-19, 21-23, 25-30, 32-35, 37-42, 44, 45, 47, 48] with 13,565 patients, there were no significant differences in mortality between the steroid and nonsteroid treatment groups (RR � 0.95; 95% CI: 0.80-1.13; p � 0.57, I 2 � 78%, p < 0.0001) ( Figure 2 ). e sensitivity analysis showed that the exclusion of three studies [18, 21, 33] changed the above conclusion.

Critically Ill COVID- 19 Patients. In the 5 included studies [22, 31, 36, 44, 46] with 1,564 critically ill COVID-19 patients, there were no significant differences in mortality between the steroid and nonsteroid treatment groups (RR � 0.89; 95% CI: 0.62-1.27; p � 0.52, I 2 � 78%, p � 0.001) ( Figure 3 ).

Twenty-three studies reported the severity data of the COVID-19 patients. In the included studies [12, 17, 18, 22, 24, 26-33, 35, 36, 38-40, 42, 44-46, 48] with 12,473 patients, there were significant differences in severe disease condition between the steroid and nonsteroid treatment groups (RR � 1.10; 95% CI, 1.03-1.19, p � 0.007) ( Figure 4 ). ere was significant heterogeneity among the studies (I 2 � 99% p < 0.001); the random-effects model was used.

To assess the small-study effect and publication bias, the regression-based Egger's test was performed. e funnel-plot analysis showed a symmetrical shape for mortality ( Figure 5 ), indicating no publication bias; Egger's test indicated nonsignificant small-study effects (p � 0.570). e funnel-plot analysis showed asymmetrical shape for severe cases ( Figure 6 ), indicating publication bias; Egger's test indicated significant small-study effects for severe cases (p � 0.027).

3.6. Sensitivity Analysis. Sensitivity analysis for betweenstudy heterogeneity and analytical methods was performed to show the robustness of the finding. e analysis showed that the result was stable except for the exclusion of three studies [18, 21, 33] that changed the conclusion ( Figure 7 ). e rationale for the use of corticosteroids is to decrease the host inflammatory responses in the lungs, which may lead to acute lung injury and acute respiratory distress syndrome [6] . Because of the high amount of cytokines induced by COVID-19 infection, corticosteroids were used frequently for the treatment of patients with severe illness, for possible benefit by reducing inflammatory-induced lung injury [24] . ere were potential harms and a lack of proven benefit for corticosteroid cautions against their routine use in patients with COVID-19 [6] .

Our analysis demonstrated that the mortality rate was comparable in COVID-19 patients treated with corticosteroids versus noncorticosteroids. However, in patients with critically ill COVID-19 patients, even though nonsignificant (RR � 0.89; 95% CI: 0.62-1.27; p � 0.52), a lower mortality rate in corticosteroid treatment groups was observed. Evidence suggests that cytokine storm, a hyperinflammatory state resembling secondary hemophagocytic lymphohistiocytosis (HLH), is a contributing factor in COVID-19-associated mortality [49] .

In our finding, there were no significant differences in mortality between the corticosteroid and noncorticosteroid treatment groups in critically ill COVID-19 patients. e initial clinical trial results from the United Kingdom (UK) showed that dexamethasone, a corticosteroid, can be lifesaving for patients who are critically ill with COVID-19. For patients on ventilators, the treatment was shown to reduce mortality by about one-third, and for patients requiring only oxygen, mortality was cut by about one-fifth, according to preliminary findings shared with the World Health Organization (WHO) [50] . e most commonly invoked rationale for giving steroids in patients with severe COVID-19 is to modulate the destructive inflammatory immune response that occurs with advancing disease. e guidelines recommend against using corticosteroids to try to modulate the immune system in mechanically ventilated COVID-19 patients without acute Studies included in meta-analysis (n = 32) Low risk of bias Low risk of bias Low risk of bias a: representativeness of the exposed cohort, b: selection of the nonexposed cohort, c: ascertainment of exposure, d: demonstration that the outcome of interest was not present at the start of the study, e: comparability of cohorts based on the design or analysis, f: assessment of outcome, g: follow-up long enough for outcomes to occur, h: adequacy of follow-up of the cohort; i: random sequence generation (selection bias), j: allocation concealment (selection bias), k: blinding of participants and personnel (performance bias), l: blinding of outcome assessment (detection bias), m: incomplete outcome data (attrition bias), n: selective reporting (reporting bias).

Study or subgroup Interdisciplinary Perspectives on Infectious Diseases respiratory distress syndrome (ARDS) but do recommend steroids in those with COVID-19 and ARDS [51] . Our finding demonstrates that there is an association between severe COVID-19 and corticosteroid therapy (RR � 1.10; 95% CI, 1.03-1.19, p � 0.007).

A previous meta-analysis in persons with SARS-CoV-2, SARS-CoV, or MERS-CoV (Middle East respiratory syndrome coronavirus) infection indicated that corticosteroid did not significantly reduce the risk of death [52] . Another meta-analysis that included 5 studies indicated a lack of benefit of corticosteroid therapy on mortality in critically ill patients with COVID-19 [53] . In addition, a review that included 15 studies with coronavirus-infected patients (2 studies with COVID-19 patients) showed that corticosteroid treatment was associated with higher mortality and critical patients were more likely to require corticosteroids therapy [54] .

Some of the limitations of this meta-analysis are as follows: the included studies are retrospective cohort studies, there is a high degree of between-study heterogeneity, and mortality may be influenced by other therapeutic options. 

No significant differences in mortality between the corticosteroid and noncorticosteroid treatment groups were observed. ere was no significant reduction in mortality in critically ill COVID-19 patients treated with corticosteroids. More randomized clinical trials are needed to further verify this conclusion.

Acute respiratory distress syndrome CI:

Confidence interval HLH:

Hemophagocytic lymphohistiocytosis ICU:

Intensive care unit MERS-CoV:

Middle east respiratory syndrome coronavirus NOS:

Newcastle-Ottawa scale PRISMA: Preferred reporting items for systematic reviews and meta-analyses RCT:

Randomized controlled trial RR:

Risk ratio SARS-CoV-2:

Severe acute respiratory syndrome coronavirus 2 UK:

United Kingdom WHO:

World Health Organization.

e data presented are properly cited and can be obtained from already published original research articles, which are available on electronic databases. 

Clinical characteristics of 2019 novel coronavirus infection in China

A novel coronavirus from patients with pneumonia in China

World Health Organization; Coronavirus Disease

COVID-19 Coronavirus Pandemic

Clinical characteristics associated with COVID-19 severity in California

Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review

Drug evaluation during the COVID-19 pandemic

Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Rapid review for the anti-coronavirus effect of remdesivir

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

Impact of corticosteroid treatment in patients with coronavirus disease 2019

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

On the use of corticosteroids for 2019-nCoV pneumonia

Effectiveness and safety of glucocorticoids to treat COVID-19: a rapid review and metaanalysis

Clinical Management of Severe Acute Respiratory Infection (SARI) when COVID-19 Disease Is Suspected, World Health Organization

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Early short course corticosteroids in hospitalized patients with COVID-19

e treatment and outcomes of patients with COVID-19 in Hubei, China: a multi-centered, retrospective, observational study

Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China

Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients

Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study

Clinical characteristics of coronavirus disease 2019 in China

Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: a cohort study

A retrospective controlled cohort study of the impact of glucocorticoid treatment in SARS-CoV-2 infection mortality

Clinical comorbidities, characteristics, and outcomes of mechanically ventilated patients in the State of Michigan with SARS-CoV-2 pneumonia

Corticosteroid therapy in critically ill patients with COVID-19: a multicenter, retrospective study

High-dose methylprednisolone in nonintubated patients with severe COVID-19 pneumonia

e use of methylprednisolone in COVID-19 patients: a propensity score matched retrospective cohort study

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Corticosteroid therapy for patients with severe novel Coronavirus disease 2019

Adjuvant corticosteroid therapy for critically ill patients with COVID-19

Clinical features and shortterm outcomes of 102 patients with coronavirus disease 2019 in Wuhan, China

Clinical outcomes associated with methylprednisolone in mechanically ventilated patients with COVID-19

Corticosteroid therapy for patients with COVID-19 pneumonia: a beforeafter study

Prolonged lowdose methylprednisolone in patients with severe COVID-19 pneumonia

Tocilizumab and steroid treatment in patients with COVID-19 pneumonia

Efficacy of corticosteroids in non-intensive care unit patients with COVID-19 pneumonia from the New York Metropolitan region

Role of low-molecular-weight heparin in hospitalized patients with severe acute respiratory syndrome coronavirus 2 pneumonia: a prospective observational study

Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report

Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial

Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19

Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial

Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19

Assessment of Evidence for COVID-19-Related Treatments

World Health Organization, WHO Welcomes Preliminary Results about Dexamethasone Use in Treating Critically Ill

Despite guidelines, controversy remains over corticosteroids in COVID-19

Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis

e role of corticosteroids in the management of critically ill patients with coronavirus disease 2019 (COVID-19): a metaanalysis

e effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis